Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 67

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models

Broz, D. K., Attardi, L. D. · 2010 · Carcinogenesis

Abstract

p53 is a crucial tumor suppressor, as evidenced by the high propensity for p53 mutation during human cancer development. Already more than a decade ago, p53 knockout mice confirmed that p53 is critical for preventing tumorigenesis. More recently, a host of p53 knock-in mouse strains has been generated, with the aim of either more precisely modeling p53 mutations in human cancer or better understanding p53's regulation and downstream activities. In the first category, several mouse strains expressing mutant p53 proteins corresponding to human-tumor-derived mutants have demonstrated that mutant p53 is not equivalent to loss of p53 but additionally exhibits gain-of-function properties, promoting invasive and metastatic phenotypes. The second class of p53 knock-in mouse models expressing engineered p53 mutants has also provided new insight into p53 function. For example, mice expressing p53 mutants lacking specific posttranslational modification sites have revealed that these modifications serve to modulate p53 responses in vivo in a cell-type- and stress-specific manner rather than being absolutely required for p53 stabilization and activation as suggested by in vitro experiments. Additionally, studies of p53 mouse models have established that both p53-driven cell-cycle arrest and apoptosis responses contribute to tumor suppression and that activation of p53 by oncogenic stress imposes an important barrier to tumorigenesis. Finally, the use of mouse strains expressing temporally regulatable p53 has demonstrated that p53 loss is not only required for tumor development but also required for tumor maintenance, suggesting that p53 restoration in human cancer patients may be a promising therapeutic strategy. These sophisticated p53 mouse models have taught us important lessons, and new mouse models will certainly continue to reveal interesting and perhaps surprising aspects of p53's complex biology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/carcin/bgp331

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 38

  1. Soussi, 2007, Oncogene, 26, 2145, 10.1038/sj.onc.1210280 · DOI · Paper page
  2. Varley, 2003, Human mutation, 21, 313, 10.1002/humu.10185 · DOI · Paper page
  3. Clarke, 1993, Nature; Physical Science (London), 362, 849, 10.1038/362849a0 · DOI · Paper page
  4. Donehower, 1995, Genes & Development, 9, 882, 10.1101/gad.9.7.882 · DOI · Paper page
  5. Donehower, 1992, Nature; Physical Science (London), 356, 215, 10.1038/356215a0 · DOI · Paper page
  6. Jacks, 1994, Current biology : CB, 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
  7. Vousden, 2002, Nature reviews. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
  8. Attardi, 1999, Cellular and molecular life sciences : CMLS, 55, 48, 10.1007/s000180050269 · DOI · Paper page
  9. Tsukada, 1993, Oncogene, 8, 3313
  10. Ihrie, 2004, Cell cycle (Georgetown, Tex.), 3, 267, 10.4161/cc.3.3.722 · DOI
  11. Kuperwasser, 2000, American Journal Of Pathology, 157, 2151, 10.1016/S0002-9440(10)64853-5 · DOI · Paper page
  12. Jonkers, 2001, Nature genetics, 29, 418, 10.1038/ng747 · DOI · Paper page
  13. Artandi, 2000, Nature; Physical Science (London), 406, 641, 10.1038/35020592 · DOI · Paper page
  14. 2001, 277, 15
  15. Lavigueur, 1989, Molecular and Cellular Biology, 9, 3982, 10.1128/MCB.9.9.3982 · DOI · Paper page
  16. Harvey, 1995, Nature genetics, 9, 305, 10.1038/ng0395-305 · DOI · Paper page
  17. Song, 2007, Nature Cell Biology, 9, 573, 10.1038/ncb1571 · DOI · Paper page
  18. Terzian, 2008, Genes & Development, 22, 1337, 10.1101/gad.1662908 · DOI · Paper page
  19. Murray-Zmijewski, 2008, Nature reviews. Molecular cell biology, 9, 702, 10.1038/nrm2451 · DOI · Paper page
  20. Armata, 2007, Cancer Research, 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI
  21. Chao, 2006, The EMBO Journal, 25, 2615
  22. Luo, 2001, Oncogene, 20, 320, 10.1038/sj.onc.1204080 · DOI
  23. Feng, 2006, Cell cycle (Georgetown, Tex.), 5, 2812, 10.4161/cc.5.23.3526 · DOI
  24. Lin, 2005, Nature Cell Biology, 7, 165, 10.1038/ncb1211 · DOI · Paper page
  25. Chao, 2006, Molecular and Cellular Biology, 26, 6859, 10.1128/MCB.00062-06 · DOI
  26. Tang, 2008, Cell, 133, 612, 10.1016/j.cell.2008.03.025 · DOI · Paper page
  27. Lin, 1994, Genes & Development, 8, 1235, 10.1101/gad.8.10.1235 · DOI · Paper page
  28. Johnson, 2005, Nature genetics, 37, 145, 10.1038/ng1498 · DOI
  29. Hammond, 2006, Molecular and Cellular Biology, 26, 3492, 10.1128/MCB.26.9.3492-3504.2006 · DOI
  30. 2008, PNAS, 105, 1215, 10.1073/pnas.0706764105 · DOI
  31. 2007, Molecular and Cellular Biology, 27, 1425, 10.1128/MCB.00999-06 · DOI · Paper page
  32. Yin, 1997, Nature; Physical Science (London), 385, 637, 10.1038/385637a0 · DOI · Paper page
  33. Schmitt, 2002, Cancer cell, 1, 289, 10.1016/S1535-6108(02)00047-8 · DOI · Paper page
  34. 2006, PNAS, 103, 19842, 10.1073/pnas.0606343104 · DOI
  35. Halazonetis, 2008, Science, 319, 1352, 10.1126/science.1140735 · DOI · Paper page
  36. Christophorou, 2005, Nature genetics, 37, 718, 10.1038/ng1572 · DOI · Paper page
  37. Hinkal, 2009, 4, e6654, 10.1371/journal.pone.0006654 · DOI
  38. Efeyan, 2006, Nature; Physical Science (London), 443, 159, 10.1038/443159a · DOI

Cited by

Metadata

Authors
Broz, D. K., & Attardi, L. D.
Venue
Carcinogenesis
Published
2010-01-22
Volume
31
Issue
8
Pages
1311-1318
ISSN
  • 0143-3334
  • 1460-2180
Cited by
67
References
26
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.